By Drug Class / Mechanism

Echinocandins & Azole Antifungals Market Analysis

Cross-industry research covering Echinocandins & Azole Antifungals across 1 market reportspanning Pharmaceuticals.

1 Reports

1 Industries

Reports Covering Echinocandins & Azole Antifungals

Hospital Acquired Infection Control Market to Reach USD 41.6B by 2033 at 6.4% CAGR

Pharmaceuticals·Market: USD 25.3 Billion (2025)·CAGR: 6.4%

Biosimilar caspofungin approved in Europe is executing a classic erosion curve, compressing net price 15–20% while volume grows as azole resistance (nct:NCT06532227) forces stewardship committees to favor echinocandins over triazoles in high-risk ICU patients. Olorofim (F2G) represents the most advanced next-class antifungal in the pipeline, with orphan designation in the EU.

13%

Market Share

7.0%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments